Trending News

Cyclospora Outbreak Update: What You Need to Know

Cyclospora Outbreak Update: What You Need to Know

Health officials are continuing to investigate a multistate outbreak of Cyclospora infections linked to contaminated iceberg lettuce. While the recalled lettuce is no longer expected to be on store shelves or in restaurants, new illnesses continue to be identified as the investigation moves forward as of mid August 2026. At the same time, Taylor Fresh Foods has...

A New Donor Immune Cells Treatment for Preventing Serious Complications in Blood Cancer Patients Has Been Approved

A New Donor Immune Cells Treatment for Preventing Serious Complications in Blood Cancer Patients Has Been Approved

The U.S. Food and Drug Administration recently approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). It represents a novel approach to allogeneic hematopoietic stem cell transplantation in some adult patients with high-risk blood cancers. It addresses an important unmet need in transplantation, where curing the cancer is often only part of the challenge; avoiding chronic GVHD is equally important for long-term outcomes.

BAXFENDY™: A New FDA-Approved Treatment Option for High Blood Pressure

BAXFENDY™: A New FDA-Approved Treatment Option for High Blood Pressure

What is it prescribed for? BAXFENDY is prescribed for adults with high blood pressure (hypertension). High blood pressure is a common condition that increases the risk of heart attack, stroke, heart failure, and kidney disease if left untreated. Many patients need more than one medication to control their blood pressure properly. BAXFENDY combines two medicines into...